A Special Omega-3 Form Raises Brain EPA, But Not DHA, and Effects Differ by Alzheimer’s Gene Type
This animal study looked at how a form of omega-3 fats called lysophosphatidylcholine (LPC) omega-3—thought to cross into the brain more easily—affects levels of EPA and DHA in the frontal cortex. The mice used carried either the APOE3 or APOE4 gene variant; APOE4 is a well-known genetic risk factor linked to Alzheimer’s disease in humans.
Mice received either LPC omega-3 (a mix of DHA and EPA) or a sunflower oil control by daily dosing for two or four months. Researchers then measured fatty acid levels in brain tissue.
After two months, EPA rose in the brains of APOE3 mice but not APOE4 mice, while DHA didn’t change significantly in either group. After four months, EPA increased in both APOE3 and APOE4 mice, but DHA levels still did not show a statistically significant rise in either group.
What this means for you
This early-stage animal research suggests that this particular omega-3 form may raise brain EPA levels over time, but getting DHA into brain tissue this way appears more difficult, and the timing and genetic background of the animal seemed to matter. These findings are from mice, not humans, so they help guide future research rather than tell us how omega-3 supplements affect the human brain.
Ready to start? The ALP Protocol delivers the EPA & DHA doses used in the research.
Start the ALP ProtocolSource
Prostaglandins, leukotrienes, and essential fatty acids · 2025-04-01 · DOI: 10.1016/j.plefa.2024.102661
Read the original source ↗This summary is for educational purposes only and is not medical advice. Always talk to your healthcare provider before making changes to your supplement routine.